United Therapeutics Corp
XMUN:UTH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
U
|
United Therapeutics Corp
XMUN:UTH
|
US |
|
C
|
Canopy Growth Corp
SWB:11L
|
CA |
|
DHT Holdings Inc
NYSE:DHT
|
BM |
|
F
|
Fujitsu Ltd
DUS:FUJ1
|
JP |
|
K
|
KGL Resources Ltd
OTC:KGLLF
|
AU |
United Therapeutics Corp
United Therapeutics is a biotechnology company focused on serious, long-term diseases where patients often need ongoing treatment. Its main business is making medicines for pulmonary hypertension, a condition that raises blood pressure in the lungs and can become life threatening. The company also works on organ manufacturing and transplant-related technologies, which reflects its goal of finding treatments for patients with very limited options. The company sells prescription drugs to doctors, hospitals, specialty pharmacies, and patients who need chronic therapy. Its revenue mainly comes from drug sales, especially branded therapies used over long periods rather than one-time treatments. Because these medicines are often prescribed by specialists and managed through complex care channels, the company depends on deep relationships with pulmonary hypertension centers, transplant specialists, and specialty distributors. What makes United Therapeutics different is that it sits at the intersection of rare-disease drug development and transplant medicine. It is not a broad pharmaceutical company with many everyday drugs; instead, it concentrates on a narrow set of severe conditions and builds expertise around them. That gives it a business model tied to specialized physicians, careful patient management, and treatment areas where medical need is high and alternatives are limited.
United Therapeutics is a biotechnology company focused on serious, long-term diseases where patients often need ongoing treatment. Its main business is making medicines for pulmonary hypertension, a condition that raises blood pressure in the lungs and can become life threatening. The company also works on organ manufacturing and transplant-related technologies, which reflects its goal of finding treatments for patients with very limited options.
The company sells prescription drugs to doctors, hospitals, specialty pharmacies, and patients who need chronic therapy. Its revenue mainly comes from drug sales, especially branded therapies used over long periods rather than one-time treatments. Because these medicines are often prescribed by specialists and managed through complex care channels, the company depends on deep relationships with pulmonary hypertension centers, transplant specialists, and specialty distributors.
What makes United Therapeutics different is that it sits at the intersection of rare-disease drug development and transplant medicine. It is not a broad pharmaceutical company with many everyday drugs; instead, it concentrates on a narrow set of severe conditions and builds expertise around them. That gives it a business model tied to specialized physicians, careful patient management, and treatment areas where medical need is high and alternatives are limited.
Revenue: United Therapeutics reported first-quarter revenue of $782 million, with management saying winter weather and pharmacy operations issues slowed starts during the quarter, especially in February.
Tyvaso: Tyvaso generated $458 million in the quarter; nebulized sales were a bit soft, but Tyvaso DPI delivered 9% year-over-year growth on stronger patient demand.
Pipeline: Management said both TETON studies in IPF and ADVANCE OUTCOMES for ralinepag were highly positive, and it is now preparing for filings and launch work.
Ralinepag: The company unveiled RALDPI, an inhaled ralinepag program being developed with MannKind, and said a Phase I study should be completed before year-end.
Outlook: Executives said they expect to return to sequential growth soon and remain confident in sustained double-digit long-term growth, with a path to a roughly $4 billion revenue run rate by 2027.
